GOLD 2017: what change were made in global strategy of treatment of chronic obstructive pulmonary disease and why?
https://doi.org/10.18093/0869-0189-2017-27-2-274-282
Abstract
In 1997, the International Expert group on chronic obstructive pulmonary disease (COPD) has come to decision to initiate the Global Initiative for COPD (GOLD). The first GOLD report was published in 2001 and provided the basis for many national programs for COPD diagnosis and management. Research data accumulated in the next decade allowed to perform complete revision of global strategy in 2011 (updated 2013), considering personalized approach to prognosis and treatment selection in an individual patient. At the end of2016, anew comprehensive reassessment of GOLD report was released. The ABCD assessment tool has been refined; the role of spirometry in COPD management has been updated. Regular assessment of inhaler technique to improve the disease control has been emphasized. New data on therapy with long-acting β2-agonists/long acting anticholinergic combinations and «triple therapy» have been added. Classification of severity of COPD exacerbations was provided and impact of concomitant diseases was stressed. The section on pulmonary rehabilitation has been amplified.
Keywords
chronic obstructive pulmonary disease,
Global Initiative for chronic obstructive pulmonary disease,
spirometry,
pharmacotherapy
Supporting agencies: GlaxoSmithKline PLC
About the Author
E. N. Barabanova
GlaxoSmithKline Trading PLC
Russian Federation
Russian Federation
Ekaterina N. Barabanova, Candidate of Medicine, Manager on Medical and Scientific Communication
ul. Krylatskaya 17, build. 3, Moscow, 121614
References
1. Lange P., Celli B., Agusti A. et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 2015; 373 (2): 111–122. DOI: 10.1056/NEJMoa1411532.
2. Vas Fragoso C.A., McAvay G., Van Ness P.H. et al. Phenotype of normal spirometry in an aging population. Am. J. Respir. Crit. Care Med. 2015; 192 (7): 817–825. DOI: 10.1164/rccm.201503-0463OC.
3. Vas Fragoso C.A., McAvay G., Van Ness P.H. et al. Phenotype of spirometric impairment in an aging population. Am. J. Respir. Crit. Care Med. 2016; 193 (7): 727–735. DOI: 10.1164/rccm.201508-1603OC.
4. Lee P.N., Fariss M.W. A systematic review of possible serious adverse effects of nicotine replacement therapy. Arch. Toxicol. 2017; 91 (4): 1565–1594. DOI: 10.1007/s00204-016-1856-y.
5. McNeill A., Brose L.S., Calder R.I. et al. E-cigarettes: an evidence update. A report commissioned by Public Health England: Public Health England, 2015. Available at: https:// www.gov.uk/government/uploads/system/uploads/attach-ment-data/file/457102/Ecigarettes-an-evidence-update-A-report-commissioned-by-Public-Health-England-FINAL.pdf
6. McRobbie H., Bullen C., Hartmann-Boyce J., Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst. Rev. 2014; (12): CD010216. DOI: 10.1002/14651858.CD010216.pub2.
7. Kalkhoran S., Glantz S.A. E-cigarettes and smoking cessation – Author’s reply. Lancet Respir. Med. 2016; 4 (6): e26–27. DOI: 10.1016/S2213-2600(16)30025-X.
8. Malas M., van der Tempel J., Schwartz R. et al. Electronic cigarettes for smoking cessation: A systematic review. Nicotine Tob. Res. 2016; 18 (10): 1926–1936. DOI: 10.1093/ntr/ntw119.
9. Souza M.L., Meneghini A.C., Ferraz E. et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J. Braz. Pneumol. 2009; 35 (9): 824–831.
10. Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938. DOI: 10.1016/j.rmed.2011.01.005.
11. Sanchis J., Gich I., Pedersen S. Systematic review of errors in inhaler use: Has patient technique improved over time? Chest. 2016; 150 (2):394–406. DOI: 10.1016/j.chest.2016.03.041.
12. Sulaiman I., Cushen B., Greene G. et al. Objective assessment of adherence to inhalers by COPD patients. Am. J. Respir. Care Med. 2017; 195 (10): 1333–1343. DOI: 10.1164/rccm.201604-0733OC.
13. Rootmensen G.N., van Keimpena A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped method. J. Aerosol Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328. DOI: 10.1089/jamp.2009.0785.
14. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, doubleblind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI: 10.1016/S2213-2600(13)70052-3.
15. Wedzicha J.A., Banerji D., Chapman K. et al. Indacaterolglycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.
16. Brusselle G., Price D., Gruffydd-Jones K. et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2207–2217. DOI: 10.2147/COPD.S91694.
17. Singh D., Brooks J., Hagan G. et al. Superiority of “triple” therapy with salmeterol-fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63 (7): 592–598. DOI: 10.1136/thx.2007.087213.
18. Frith P.A., Thompson P.J., Ratnavadivel R. et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD – a randomized controlles trial. Thorax. 2015; 70 (6): 519–527. DOI: 10.1136/thoraxjnl2014-206670.
19. Siler T.M., Kerwin E., Singletary K. et al. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD. 2016; 13 (1): 1–10. DOI: 10.3109/15412555.2015.1034256.
20. Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus ling-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI: 10.1016/S0140-6736(16)31354-X.
21. McCarthy B., Casey D., Devane D. et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; (2): CD003793. DOI: 10.1002/14651858.CD003793.pub3.
22. Galli J.A., Krahnke J.S., James Mamary A. et al. Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. Respir. Med. 2014; 108 (5): 722–728. DOI: 10.1016/j.rmed.2014.03.006.
23. Coughlin S., Liang W.E., Parthasarathy S. Retrospective assessment of home ventilation to reduce rehospitalization in chronic obstructive pulmonary disease. J. Clin. Sleep Med. 2015; 11 (6): 663–670. DOI: 10.5664/jcsm.4780.
24. Marin J.M., Soriano J.B., Carrizo S.J. et al. Outcomes in patients with in chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir. Crit. Care Med. 2010; 182 (3): 325–331. DOI: 10.1164/rccm.200912-1869OC.
25. Gavish R., Levy A., Dekel O.K. et al. The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. Chest. 2015; 148 (2): 375–381. DOI: 10.1378/chest.14-1453.
26. Masa J.F., Utrabo I., Gomez de Terreros J. et al. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units: precision medicine in intermediate care units. BMC Pulm. Med. 2016; 16 (1): 97. DOI: 10.1186/s12890-016-0262-9.
27. Houben-Wilke S., Jorres R.A., Bals R. et al. Peripheral artery disease and its clinical relevance in patients with COPD in the COSYCONET study. Am. J. Respir. Crit. Care Med. 2017; 195 (2): 189–197. DOI: 10.1164/rccm.2016020354OC.
28. Bhatt S.P., Dransfield M.T. Chronic obstructive pulmonary disease and cardiovascular disease. Transl. Res. 2013; 162 (4): 237–251. DOI: 10.1016/j.trsl.2013.05.001.
29. Jaramillo J.D., Wilson C., Stinson D.S. et al. Reduced bone density and vertebral fractures in smokers. Men and COPD patients at increased risk. Ann. Am. Thorac. Soc. 2015; 12 (5): 648–656. DOI: 10.1513/AnnalsATS.201412-591OC.
30. de Torres J.P., Wilson D.O., Sanchez-Salcedo P. et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am. J. Respir. Crit. Care Med. 2015; 191 (3): 285–291. DOI: 10.1164/rccm.2014071210OC.
31. Sasaki T., Nakayama K., Yasuda H. et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patient. J. Am. Geriatr. Soc. 2009; 57 (8): 1453–1457.
Review
For citations:
Barabanova E.N. GOLD 2017: what change were made in global strategy of treatment of chronic obstructive pulmonary disease and why? PULMONOLOGIYA. 2017;27(2):274-282. (In Russ.) https://doi.org/10.18093/0869-0189-2017-27-2-274-282
Views:
20513
Email this article 